Literature DB >> 23105593

Significance of tumor markers in lung cancer.

P P Mumbarkar1, A S Raste, M S Ghadge.   

Abstract

The objective was to test the utility of the cytokeratins CYFRA 21-1, tissue polypeptide specific antigen (TPS), Neuron specific enolase (NSE) and Carcino Embryonic antigen (CEA) in patients with lung cancer and in the pleural fluid of the patients with lung cancer and also the predicting ability of these tumor markers with respect to the histological types [including non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] and pathological stages. 40 normal subjects and 222 cases of histological proven lung cancer were studied. The findings suggest that TPS and CYFRA 21-1, are useful serum markers for the diagnosis of NSCLC and NSE seems to be useful tumor marker for monitoring course of patients especially SCLC. The combined use of these cytokeratin markers TPS and CYFRA 21-1 may provide additional information for prognosis.

Entities:  

Year:  2006        PMID: 23105593      PMCID: PMC3453782          DOI: 10.1007/BF02913090

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  9 in total

1.  Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer.

Authors:  J W van Putten; P Baas; H Codrington; H B Kwa; M Muller; N Aaronson; H J Groen
Journal:  Lung Cancer       Date:  2001 Aug-Sep       Impact factor: 5.705

Review 2.  Lung tumor markers of cytokeratin origin: an overview.

Authors:  G Buccheri; D Ferrigno
Journal:  Lung Cancer       Date:  2001-12       Impact factor: 5.705

Review 3.  Clinical applications of serum markers for lung cancer.

Authors:  D Ferrigno; G Buccheri
Journal:  Respir Med       Date:  1995-10       Impact factor: 3.415

4.  Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook.

Authors:  B Björklund
Journal:  Antibiot Chemother (1971)       Date:  1978

5.  Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.

Authors:  R S Lai; C C Chen; P C Lee; J Y Lu
Journal:  Jpn J Clin Oncol       Date:  1999-09       Impact factor: 3.019

6.  Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.

Authors:  Fabrice Barlési; Céline Gimenez; Jean-Philippe Torre; Christophe Doddoli; Julien Mancini; Laurent Greillier; François Roux; Jean-Pierre Kleisbauer
Journal:  Respir Med       Date:  2004-04       Impact factor: 3.415

7.  Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.

Authors:  G F Buccheri; D Ferrigno; A M Sartoris; B Violante; F Vola; A Curcio
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

Review 8.  Tumor markers. An update.

Authors:  R J Pamies; D R Crawford
Journal:  Med Clin North Am       Date:  1996-01       Impact factor: 5.456

9.  Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies.

Authors:  J L Broers; F C Ramaekers; M K Rot; T Oostendorp; A Huysmans; G N van Muijen; S S Wagenaar; G P Vooijs
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

  9 in total
  7 in total

1.  Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime.

Authors:  Xiang Ao; Jie Zhou; Hong Ling Liang; Ming Jiang; Hong Sheng Li
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

2.  Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer.

Authors:  Wei Zhao; Haixiang Yu; Zhifeng Han; Nan Gao; Jinru Xue; Yan Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Ping Gu; Gang Huang; Yumei Chen; Cuiying Zhu; Jimin Yuan; Shile Sheng
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 4.  Usage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey.

Authors:  Chirag Desai; Anurag Mehta; Divya Mishra
Journal:  Lung India       Date:  2014-07

5.  Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.

Authors:  Limin Niu; Xingguo Song; Ning Wang; Linlin Xue; Xianrang Song; Li Xie
Journal:  Cancer Sci       Date:  2018-12-06       Impact factor: 6.716

6.  Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples.

Authors:  Galina S Zamay; Tatiana N Zamay; Vasilii A Kolovskii; Alexandr V Shabanov; Yury E Glazyrin; Dmitry V Veprintsev; Alexey V Krat; Sergey S Zamay; Olga S Kolovskaya; Ana Gargaun; Alexey E Sokolov; Andrey A Modestov; Ivan P Artyukhov; Nikolay V Chesnokov; Marina M Petrova; Maxim V Berezovski; Anna S Zamay
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

7.  D-dimer level is related to the prognosis of patients with small cell lung cancer.

Authors:  Xuqin Jiang; Xiaodong Mei; Huimei Wu; Xiaojuan Chen
Journal:  Ann Transl Med       Date:  2017-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.